Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Okta, Inc. (OKTA) vs Vir Biotechnology Inc. Common Stock (VIR) Price & Performance

Okta, Inc.Trade
Vir Biotechnology Inc. Common StockTrade

Price performance (Past 24H)

Key statistics

Okta, Inc. vs Vir Biotechnology Inc. Common Stock — how do they compare? Okta, Inc. trades at $205 (market cap $37.05B), while Vir Biotechnology Inc. Common Stock trades at $10.2 (market cap $1.76B). The key difference: Okta, Inc. is far larger — about 21.1× Vir Biotechnology Inc. Common Stock's market cap, and Okta, Inc. is more actively traded (4,638,855 versus 2,764,948). Which is the better fit depends on your goals — on Pluang, investors hold Okta, Inc. for 44 Days and Vir Biotechnology Inc. Common Stock for 0 Days on average.

OKTAVIR
Market Cap
$37.05B$1.76B
Volume
4,638,8552,764,948
Sector
TechnologyHealth
52-Week High
$232.13$11.78
52-Week Low
$62.93$5.12
Typical Hold Time
44 Days0 Days
Enterprise Value
$34.80B$1.32B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Okta, Inc.

OKTA trades at $226.53, showing modest daily weakness with a 0.24% decline. The stock maintains strong bullish technical momentum with consistent earnings beats and positive analyst sentiment. Recent developments include the company's AI Agent Security Blueprint Alliance announcement at Oktane 2026, positioning Okta for growth in the emerging AI security market. Fundamental improvements show revenue growth from $2.3B in 2024 to $2.6B in 2025, with the company achieving profitability after several years of losses.

Outlook remains positive with 74% analyst buy ratings and a $245 high price target, though valuation multiples appear stretched with P/E of 136. Key risks include competitive pressures in cybersecurity and the stock's premium valuation. The transition to profitability and AI security positioning provide catalysts, but investors should monitor execution against growth expectations.

Vir Biotechnology Inc. Common Stock

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

OKTA
20% Buy80% Sell
Avg holding period · 44 Days
VIR
51% Buy49% Sell
Avg holding period · 0 Days

About Okta, Inc.

Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.

Read more on OKTA →

About Vir Biotechnology Inc. Common Stock

Vir Biotechnology, Inc. is a US clinical-stage biopharmaceutical company that develops monoclonal antibody-based medicines to treat and prevent serious infectious diseases.

Read more on VIR →